Free delivery on orders over £40 Oral weight loss is here UK-registered prescribers, GPhC regulated Free delivery on orders over £40 Oral weight loss is here UK-registered prescribers, GPhC regulated Free delivery on orders over £40 Oral weight loss is here UK-registered prescribers, GPhC regulated

What Real Weight Loss Looks Like on Wegovy – Before and After

Date: 28 / May / 2026

When people search for Wegovy before and after results, they are usually looking for reassurance. They want to know whether the treatment actually works, how long results take, and what a realistic outcome looks like for someone like them. At Everslim, we believe the most useful answer to those questions comes not from transformation photos, but from clinical evidence and honest expectation-setting.

This article walks through what the research shows, what patients typically experience at each stage of treatment, and what factors influence individual outcomes. If you would like to find out whether Wegovy is right for you, contact our team or start your consultation today.

Start Consultation

Please note that this article provides general information only and should not replace personalised medical advice provided through a clinical consultation.

Quick Answer

What do Wegovy before and after results look like? Clinical trials show that patients using Wegovy lose an average of 15% of their body weight over 68 weeks. Most people notice appetite changes within the first few weeks, early weight loss between months one and three, and more visible physical changes from around month three onwards. Results vary based on starting weight, dose, lifestyle, and individual response to the medication.

What Is Wegovy and How Does It Work?

Wegovy (semaglutide 2.4mg) is a once-weekly injectable weight loss treatment approved for use in the UK. It belongs to a class of medications known as GLP-1 receptor agonists, which work by mimicking a hormone naturally produced in the gut after eating.

Wegovy acts on receptors in the brain that regulate hunger and satiety, helping patients feel fuller for longer and reducing overall calorie intake. It also slows gastric emptying, which means food moves through the digestive system more gradually, further supporting appetite control.

Unlike older weight loss approaches that relied primarily on stimulants or fat-blocking mechanisms, Wegovy addresses the hormonal and neurological pathways involved in hunger. This is why clinical outcomes are substantially more significant than those seen with lifestyle interventions alone. Wegovy is generally prescribed to adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition, though eligibility criteria may vary by provider.

Before and after weight loss comparison

Wegovy Before and After: What Clinical Trials Show

The most significant evidence for Wegovy’s effectiveness comes from the STEP clinical trial programme, a series of large-scale studies conducted before the medication received regulatory approval. These trials involved thousands of participants across multiple countries and produced results that prompted widespread attention from the medical community.

Key findings from the STEP trials include:

• participants lost an average of 14.9% of their body weight over 68 weeks compared to 2.4% in the placebo group
• approximately one in three participants lost more than 20% of their body weight
• the majority of weight loss occurred progressively across the full treatment period
• benefits were observed alongside improvements in blood pressure, blood sugar levels, and cholesterol

These figures represent averages across large populations. Individual results within those trials varied considerably, which reflects the reality that responses to any medical treatment are influenced by a range of personal factors. Nevertheless, the clinical evidence for Wegovy is among the strongest of any approved weight loss medication currently available in the UK.

Every weight loss journey is different. Use our tool to understand how much weight you could lose:

Note: This calculator is based on clinical evidence. Your personal journey, lifestyle changes, and medical history can all impact progress. Talk to our team for more personalised advice.

What Changes Can You Expect in the First Month?

The first month of Wegovy treatment is an adjustment period. Patients begin at the lowest dose of 0.25mg weekly, which is not a therapeutic dose but rather a starting point to allow the body to adapt gradually. This approach is designed to reduce the likelihood of gastrointestinal side effects such as nausea, which are more common early in treatment.

During this phase, many patients notice:

• a modest reduction in appetite, even at the low starting dose
• feeling satisfied more quickly when eating
• some nausea, particularly in the first week or two, which often settles
• minimal weight change on the scales, as the dose is introductory

It is important not to judge the treatment’s effectiveness by the first month alone. The dose during this period is not intended to produce significant weight loss. Instead, the goal is tolerability and preparation for the higher doses that follow.

Weeks 4 to 12: Early Progress and Appetite Changes

From week five onwards, the dose increases to 0.5mg. Further increases follow at four-weekly intervals, with the target maintenance dose of 2.4mg typically reached around week 17. As doses increase through this phase, appetite suppression becomes more pronounced.

During weeks four to twelve, patients commonly experience:

• a noticeably reduced desire to eat between meals
• smaller portion sizes feeling satisfying
• the beginning of measurable weight loss
• occasional side effects such as nausea or constipation, which tend to reduce as the body adjusts
• increased awareness of fullness cues that may have been dulled before treatment

Weight loss during this period is real but often modest in absolute terms. Many patients lose between two and five percent of their starting body weight in the first three months, though this varies. The changes happening hormonally and metabolically during this period lay the foundation for more significant results in the months that follow.

Months 3 to 6: When Most People Notice Visible Results

For many patients, the period between months three and six is when before and after differences become more noticeable, both to themselves and to others. By this point, the dose is approaching or has reached its higher therapeutic levels, and the cumulative effect of reduced calorie intake over several months is becoming apparent.

Changes patients frequently report during this phase include:

• clothing fitting more loosely
• visible changes in facial and abdominal contour
• improved energy levels and mobility
• greater confidence in food choices and appetite management
• continued steady weight loss, often in the range of one to two pounds per week

It is also during this period that the importance of clinical support becomes clear. Dose reviews, monitoring of side effects, and guidance on maintaining healthy habits all contribute to sustaining progress. Patients supported by a regulated clinic tend to navigate this phase more effectively than those accessing medication without clinical oversight.

Wegovy Before and After at 12 Months: The Bigger Picture

By the twelve-month mark, patients who have remained on treatment and tolerated dose titration well typically represent the clearest picture of what Wegovy can achieve. The STEP trial data showing average losses of around 15% of body weight was measured at 68 weeks, and twelve months falls within this window for most patients who started treatment with the standard titration schedule.

To put this in practical terms:

Starting WeightAverage 15% LossWeight After 12 Months
100kg15kg~85kg
120kg18kg~102kg
90kg13.5kg~76.5kg
80kg12kg~68kg

These are illustrative figures based on clinical trial averages and should not be taken as a guarantee of individual outcomes. Some patients will lose more, others less. What the data does confirm is that meaningful, sustained weight loss is achievable with Wegovy as part of a clinically supervised treatment programme.

Why Results Vary Between Individuals

One of the most important things to understand about Wegovy before and after outcomes is that no two patients will have an identical experience. Several biological and behavioural factors influence how an individual responds to semaglutide.

Factors that can affect results include:

• starting BMI and total body weight
• underlying health conditions such as type 2 diabetes, which can affect the rate of weight loss
• consistency with weekly injections and dose titration schedule
• dietary habits and overall calorie intake during treatment
• physical activity levels
• sleep quality, which influences hunger hormones independently of medication
• individual variation in how the body metabolises and responds to semaglutide

Patients with a higher starting weight often see larger absolute losses, but the percentage reduction tends to align with trial averages across body sizes. Those with certain metabolic conditions may progress more gradually, though they still benefit significantly from treatment.

Happy woman enjoying outdoor exercise

Lifestyle Factors That Influence Before and After Outcomes

Wegovy is not a passive treatment. While it reduces hunger and supports appetite control, patients who make conscious adjustments to their diet and activity levels during treatment consistently achieve better outcomes than those who rely solely on the medication.

Habits that support better results include:

• eating balanced, nutrient-dense meals rather than using reduced appetite as an opportunity to skip nutrition
• staying well hydrated, which supports both weight loss and tolerability of side effects
• incorporating regular movement, even if that starts with walking rather than structured exercise
• maintaining consistent sleep patterns to support hormonal balance
• attending dose reviews and clinical check-ins to ensure the treatment plan remains appropriate

A regulated clinic provides the framework for these conversations. Clinical support is not just about the prescription; it is about helping patients build the habits that make treatment results last.

Is Wegovy or Mounjaro Better for Before and After Results?

This is one of the most common questions patients ask when researching GLP-1 treatments. Both Wegovy (semaglutide) and Mounjaro (tirzepatide) are clinically proven weight loss medications, but they work slightly differently and trial data suggests different average outcomes.

FactorWegovy (Semaglutide)Mounjaro (Tirzepatide)
MechanismGLP-1 receptor agonistDual GLP-1 and GIP receptor agonist
Average weight loss (trials)~15% body weight over 68 weeks~20% body weight over 72 weeks
Injection frequencyOnce weeklyOnce weekly
Starting dose0.25mg2.5mg
Available at EverslimYesYes

Trial data suggests Mounjaro produces greater average weight loss, but these figures come from separate studies with different participant populations and cannot be directly compared. The right choice for any individual depends on their health history, suitability assessed at consultation, and clinical recommendation. At Everslim, our prescribers review each patient individually to recommend the most appropriate treatment.

Common Questions About Wegovy Results

How Long Does It Take to See Results on Wegovy?

Most patients notice appetite changes within the first few weeks. Visible weight loss typically becomes apparent between months two and three, with the most significant changes occurring from month three to twelve. Results build gradually throughout the full treatment course.

How Much Weight Can You Lose on Wegovy in 3 Months?

In the first three months, many patients lose between five and ten percent of their starting body weight. This varies based on the pace of dose titration, individual response, and lifestyle factors. The three-month mark typically coincides with reaching higher therapeutic doses.

Will I Regain Weight When I Stop Taking Wegovy?

Clinical data indicates that a significant proportion of weight lost during Wegovy treatment can return after stopping the medication, particularly if lifestyle changes have not been embedded. This is why clinical support and sustainable habit-building during treatment are important parts of a long-term approach to weight management.

Does Wegovy Work for Everyone?

Wegovy does not produce the same results in every patient. A small proportion of patients are considered non-responders, meaning they lose less than five percent of body weight after 16 weeks at the full therapeutic dose. A prescriber will review progress and discuss whether continuing treatment is appropriate in these cases.

Can I Take Wegovy Alongside Diet and Exercise?

Yes, and doing so significantly improves outcomes. Wegovy is most effective when used alongside a reduced-calorie diet and increased physical activity. The medication supports appetite control, while healthy habits enhance the rate and sustainability of weight loss.

What Are the Most Common Side Effects of Wegovy?

The most commonly reported side effects are gastrointestinal, including nausea, constipation, diarrhoea, and vomiting. These are most likely to occur during dose increases and typically reduce over time. Starting at a low dose and titrating gradually is specifically designed to minimise these effects.

Starting Your Own Before and After Journey With Everslim

The before and after story that matters most is yours. Clinical trial data provides a benchmark, but what actually changes for you will depend on your starting point, your commitment to the process, and the quality of support you have along the way.

At Everslim, our GPhC-regulated service provides clinically supervised Wegovy treatment with ongoing support at every stage. Our prescribers assess each patient individually before treatment begins, monitor progress throughout, and are available to help when questions arise.

If you are ready to take the first step, complete our online consultation form today. Our team will review your suitability and, if appropriate, arrange for medication to be delivered directly to your home.

If you have questions before you begin, our team is always happy to help. Get in touch and we will be glad to guide you through your options.

Start Consultation

Clinically Reviewed

Medically and clinically reviewed by the Superintendent Pharmacist

Muhammad Mian MPharmS IP

Independent Prescribing Pharmacist

GPhC Registration Number: 2066548

Muhammad Mian is our Sales and Commercial Director at Everslim, as well as an experienced Independent Prescribing Pharmacist. With over 20 years in the healthcare sector, he combines deep clinical expertise with strategic insight to help drive safe, effective and personalised weight loss journeys for our patients.

All medical content on this page is reviewed for clinical accuracy, regulatory compliance and alignment with current UK prescribing standards.

Last reviewed: May 2026

Ready to Take the Next Step? Start Your Weight Loss Journey Today!

Take our short 5 minute questionnaire now.